Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures: 2013-2025

Historic Capital Expenditures for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $6.0 million.

  • Ocular Therapeutix's Capital Expenditures rose 6633.71% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 506.67%. This contributed to the annual value of $1.3 million for FY2024, which is 78.84% down from last year.
  • Per Ocular Therapeutix's latest filing, its Capital Expenditures stood at $6.0 million for Q3 2025, which was up 381.37% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Capital Expenditures ranged from a high of $6.0 million in Q3 2025 and a low of $89,000 during Q3 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $605,000 (2024), whereas its average is $1.5 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Capital Expenditures tumbled by 88.40% in 2024, and later skyrocketed by 6,633.71% in 2025.
  • Over the past 5 years, Ocular Therapeutix's Capital Expenditures (Quarterly) stood at $631,000 in 2021, then skyrocketed by 240.73% to $2.1 million in 2022, then slumped by 78.65% to $459,000 in 2023, then crashed by 55.99% to $202,000 in 2024, then soared by 6,633.71% to $6.0 million in 2025.
  • Its Capital Expenditures stands at $6.0 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.9 million for Q1 2025.